Venlafaxine in depressed geriatric outpatients: An open-label clinical study

A. Khan, R. Rudolph, Bernard Baumel, J. Ferguson, P. Ryan, R. Shrivastava

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A 12-month open-label clinical trial was conducted to evaluate patient acceptance and safety of venlafaxine, a novel antidepressant, in ambulatory geriatric depressed patients. The sample consisted of 58 depressed patients aged 65 years end older who needed long-term antidepressant treatment. The setting was multiple study sites in California, Florida, New York, Utah, and Washington. All patients took venlafaxine; 52 qualified for the intent-to- treat analysis, and 24 completed 12 months of treatment. Repeated-measures analysis of variance within subjects showed significant improvements in Clinical Global impressions severity and improvement, Modified Symptom Checklist, and Quality of Life Questionnaire scores. One patient developed a rash that was judged to be a serious drug-related side effect. The most common side effects were headache (n=25), nausea (n=21), insomnia (n=18), dry mouth (n=18), and sweating (n=18). The results demonstrate the safety and patient acceptance of venlafaxine in depressed geriatric outpatients for acute and maintenance treatment.

Original languageEnglish (US)
Pages (from-to)753-758
Number of pages6
JournalPsychopharmacology Bulletin
Volume31
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Geriatrics
Outpatients
Patient Safety
Antidepressive Agents
Sweating
Sleep Initiation and Maintenance Disorders
Exanthema
Drug-Related Side Effects and Adverse Reactions
Checklist
Nausea
Headache
Mouth
Analysis of Variance
Therapeutics
Quality of Life
Clinical Trials
Clinical Studies
Venlafaxine Hydrochloride

Keywords

  • antidepressants
  • depression
  • geriatric
  • venlafaxine

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Khan, A., Rudolph, R., Baumel, B., Ferguson, J., Ryan, P., & Shrivastava, R. (1995). Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacology Bulletin, 31(4), 753-758.

Venlafaxine in depressed geriatric outpatients : An open-label clinical study. / Khan, A.; Rudolph, R.; Baumel, Bernard; Ferguson, J.; Ryan, P.; Shrivastava, R.

In: Psychopharmacology Bulletin, Vol. 31, No. 4, 1995, p. 753-758.

Research output: Contribution to journalArticle

Khan, A, Rudolph, R, Baumel, B, Ferguson, J, Ryan, P & Shrivastava, R 1995, 'Venlafaxine in depressed geriatric outpatients: An open-label clinical study', Psychopharmacology Bulletin, vol. 31, no. 4, pp. 753-758.
Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R. Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacology Bulletin. 1995;31(4):753-758.
Khan, A. ; Rudolph, R. ; Baumel, Bernard ; Ferguson, J. ; Ryan, P. ; Shrivastava, R. / Venlafaxine in depressed geriatric outpatients : An open-label clinical study. In: Psychopharmacology Bulletin. 1995 ; Vol. 31, No. 4. pp. 753-758.
@article{319ca62e2d4f4a27ad24fc8baaf6369a,
title = "Venlafaxine in depressed geriatric outpatients: An open-label clinical study",
abstract = "A 12-month open-label clinical trial was conducted to evaluate patient acceptance and safety of venlafaxine, a novel antidepressant, in ambulatory geriatric depressed patients. The sample consisted of 58 depressed patients aged 65 years end older who needed long-term antidepressant treatment. The setting was multiple study sites in California, Florida, New York, Utah, and Washington. All patients took venlafaxine; 52 qualified for the intent-to- treat analysis, and 24 completed 12 months of treatment. Repeated-measures analysis of variance within subjects showed significant improvements in Clinical Global impressions severity and improvement, Modified Symptom Checklist, and Quality of Life Questionnaire scores. One patient developed a rash that was judged to be a serious drug-related side effect. The most common side effects were headache (n=25), nausea (n=21), insomnia (n=18), dry mouth (n=18), and sweating (n=18). The results demonstrate the safety and patient acceptance of venlafaxine in depressed geriatric outpatients for acute and maintenance treatment.",
keywords = "antidepressants, depression, geriatric, venlafaxine",
author = "A. Khan and R. Rudolph and Bernard Baumel and J. Ferguson and P. Ryan and R. Shrivastava",
year = "1995",
language = "English (US)",
volume = "31",
pages = "753--758",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "4",

}

TY - JOUR

T1 - Venlafaxine in depressed geriatric outpatients

T2 - An open-label clinical study

AU - Khan, A.

AU - Rudolph, R.

AU - Baumel, Bernard

AU - Ferguson, J.

AU - Ryan, P.

AU - Shrivastava, R.

PY - 1995

Y1 - 1995

N2 - A 12-month open-label clinical trial was conducted to evaluate patient acceptance and safety of venlafaxine, a novel antidepressant, in ambulatory geriatric depressed patients. The sample consisted of 58 depressed patients aged 65 years end older who needed long-term antidepressant treatment. The setting was multiple study sites in California, Florida, New York, Utah, and Washington. All patients took venlafaxine; 52 qualified for the intent-to- treat analysis, and 24 completed 12 months of treatment. Repeated-measures analysis of variance within subjects showed significant improvements in Clinical Global impressions severity and improvement, Modified Symptom Checklist, and Quality of Life Questionnaire scores. One patient developed a rash that was judged to be a serious drug-related side effect. The most common side effects were headache (n=25), nausea (n=21), insomnia (n=18), dry mouth (n=18), and sweating (n=18). The results demonstrate the safety and patient acceptance of venlafaxine in depressed geriatric outpatients for acute and maintenance treatment.

AB - A 12-month open-label clinical trial was conducted to evaluate patient acceptance and safety of venlafaxine, a novel antidepressant, in ambulatory geriatric depressed patients. The sample consisted of 58 depressed patients aged 65 years end older who needed long-term antidepressant treatment. The setting was multiple study sites in California, Florida, New York, Utah, and Washington. All patients took venlafaxine; 52 qualified for the intent-to- treat analysis, and 24 completed 12 months of treatment. Repeated-measures analysis of variance within subjects showed significant improvements in Clinical Global impressions severity and improvement, Modified Symptom Checklist, and Quality of Life Questionnaire scores. One patient developed a rash that was judged to be a serious drug-related side effect. The most common side effects were headache (n=25), nausea (n=21), insomnia (n=18), dry mouth (n=18), and sweating (n=18). The results demonstrate the safety and patient acceptance of venlafaxine in depressed geriatric outpatients for acute and maintenance treatment.

KW - antidepressants

KW - depression

KW - geriatric

KW - venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=0029553222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029553222&partnerID=8YFLogxK

M3 - Article

C2 - 8851649

AN - SCOPUS:0029553222

VL - 31

SP - 753

EP - 758

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 4

ER -